Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,priceHint,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchangeDataDelayedBy,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,IPSEY,639800000,331428000,103650000,,200550000,1700000,152000000,241700000,582000000,219450000,219450000,17200000,-6000000,,,,49500000,707300000,487850000,125300000,-18900000,600000,151050000,152000000,1142400000,122300000,2133200000,2386600000,89700000,4521500000,83800000,14400000,304000000,245000000,604400000,1876500000,235900000,737500000,1117000000,231000000,261700000,1977000000,645700000,1764300000,128800000,736200000,680600000,232700000,518600000,-3900000,8350000,-38800000,-51500000,-97300000,-11050000,43250000,-2900000,700000,178600000,50100000,-6350000,-41450000,-7950000,-34200000,-1450000,20400000,-17050000,647300000,en-US,US,EQUITY,False,Delayed Quote,USD,24.75,1630508081,-0.29400063,24.725,24.75,24.725,637,-1.1739364,24.725 - 24.75,25.044,0.0,0.0,0,0,finmb_135238,Other OTC,Ipsen S.A.,EUR,1578,1085,5.3999996,0.27906975,19.35 - 28.1,-3.3500004,-0.11921709,19.35,28.1,1623196800,1.0,12.632385,0.03992972,2,PNK,1.95925,6.40425,25.685371,-0.9353714,-0.036416505,24.27547,0.47452927,0.019547686,8202843136,3.8646212,15,America/New_York,EDT,-14400000,False,False,0,IPSEN SA,us_market,PRE,0.99,,,28.1,19.35,25.69,24.28,1.58k,1.08k,331.43M,,139.21M,0.00%,0.01%,,,,,,0.3,1.11%,1.00,3.99%,1.05,13.33%,"Jun 08, 2021","May 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",22.55%,29.67%,11.84%,29.47%,2.79B,8.43,8.20%,2.2B,968.1M,626.5M,1.96,37.00%,737.5M,2.23,1.07B,44.99,1.58,6.40,834.9M,502.65M,Value,92650,Healthcare,5700,9,7,"Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",Boulogne-Billancourt,33 1 58 33 50 00,7,1609372800,1625097600,8,France,http://www.ipsen.com,86400,9,"65, quai Georges Gorse",33 1 58 33 50 01,Drug Manufacturersâ€”Specialty & Generic,Cedex
t-1,IPSEY,639800000,331428000,103650000,,200550000,1700000,152000000,241700000,582000000,219450000,219450000,17200000,-6000000,,,,49500000,707300000,487850000,125300000,-18900000,600000,151050000,152000000,1142400000,122300000,2133200000,2386600000,89700000,4521500000,83800000,14400000,304000000,245000000,604400000,1876500000,235900000,737500000,1117000000,231000000,261700000,1977000000,645700000,1764300000,128800000,736200000,680600000,232700000,518600000,-3900000,8350000,-38800000,-51500000,-97300000,-11050000,43250000,-2900000,700000,178600000,50100000,-6350000,-41450000,-7950000,-34200000,-1450000,20400000,-17050000,647300000,en-US,US,EQUITY,False,Delayed Quote,USD,24.75,1630508081,-0.29400063,24.725,24.75,24.725,637,-1.1739364,24.725 - 24.75,25.044,0.0,0.0,0,0,finmb_135238,Other OTC,Ipsen S.A.,EUR,1578,1085,5.3999996,0.27906975,19.35 - 28.1,-3.3500004,-0.11921709,19.35,28.1,1623196800,1.0,12.632385,0.03992972,2,PNK,1.95925,6.40425,25.685371,-0.9353714,-0.036416505,24.27547,0.47452927,0.019547686,8202843136,3.8646212,15,America/New_York,EDT,-14400000,False,False,0,IPSEN SA,us_market,PRE,0.99,,,28.1,19.35,25.69,24.28,1.58k,1.08k,331.43M,,139.21M,0.00%,0.01%,,,,,,0.3,1.11%,1.00,3.99%,1.05,13.33%,"Jun 08, 2021","May 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",22.55%,29.67%,11.84%,29.47%,2.79B,8.43,8.20%,2.2B,968.1M,626.5M,1.96,37.00%,737.5M,2.23,1.07B,44.99,1.58,6.40,834.9M,502.65M,Value,92650,Healthcare,5700,9,7,"Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",Boulogne-Billancourt,33 1 58 33 50 00,7,1609372800,1625097600,8,France,http://www.ipsen.com,86400,9,"65, quai Georges Gorse",33 1 58 33 50 01,Drug Manufacturersâ€”Specialty & Generic,Cedex
t-2,IPSEY,405200000,331428000,107500000,,129250000,2700000,163050000,251300000,565250000,194950000,194950000,11500000,-6200000,,,,-32650000,689650000,494700000,124400000,-65700000,1200000,161900000,163050000,1121100000,122300000,2195400000,2119100000,110800000,4317200000,83800000,34200000,548000000,220700000,592800000,1365000000,251200000,642500000,1213100000,247400000,373900000,1467100000,646600000,1578800000,126700000,652000000,665200000,213900000,495200000,-1350000,16150000,-48700000,-66650000,-81150000,22450000,109400000,-15200000,400000,238850000,51300000,-10300000,-41450000,1550000,17600000,700000,-6500000,-23300000,365700000,en-US,US,EQUITY,False,Delayed Quote,USD,24.75,1630508081,-0.29400063,24.725,24.75,24.725,637,-1.1739364,24.725 - 24.75,25.044,0.0,0.0,0,0,finmb_135238,Other OTC,Ipsen S.A.,EUR,1578,1085,5.3999996,0.27906975,19.35 - 28.1,-3.3500004,-0.11921709,19.35,28.1,1623196800,1.0,12.632385,0.03992972,2,PNK,1.95925,6.40425,25.685371,-0.9353714,-0.036416505,24.27547,0.47452927,0.019547686,8202843136,3.8646212,15,America/New_York,EDT,-14400000,False,False,0,IPSEN SA,us_market,PRE,0.99,,,28.1,19.35,25.69,24.28,1.58k,1.08k,331.43M,,139.21M,0.00%,0.01%,,,,,,0.3,1.11%,1.00,3.99%,1.05,13.33%,"Jun 08, 2021","May 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",22.55%,29.67%,11.84%,29.47%,2.79B,8.43,8.20%,2.2B,968.1M,626.5M,1.96,37.00%,737.5M,2.23,1.07B,44.99,1.58,6.40,834.9M,502.65M,Value,92650,Healthcare,5700,9,7,"Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",Boulogne-Billancourt,33 1 58 33 50 00,7,1609372800,1625097600,8,France,http://www.ipsen.com,86400,9,"65, quai Georges Gorse",33 1 58 33 50 01,Drug Manufacturersâ€”Specialty & Generic,Cedex
t-3,IPSEY,405200000,331428000,107500000,,129250000,2700000,163050000,251300000,565250000,194950000,194950000,11500000,-6200000,,,,-32650000,689650000,494700000,124400000,-65700000,1200000,161900000,163050000,1121100000,122300000,2195400000,2119100000,110800000,4317200000,83800000,34200000,548000000,220700000,592800000,1365000000,251200000,642500000,1213100000,247400000,373900000,1467100000,646600000,1578800000,126700000,652000000,665200000,213900000,495200000,-1350000,16150000,-48700000,-66650000,-81150000,22450000,109400000,-15200000,400000,238850000,51300000,-10300000,-41450000,1550000,17600000,700000,-6500000,-23300000,365700000,en-US,US,EQUITY,False,Delayed Quote,USD,24.75,1630508081,-0.29400063,24.725,24.75,24.725,637,-1.1739364,24.725 - 24.75,25.044,0.0,0.0,0,0,finmb_135238,Other OTC,Ipsen S.A.,EUR,1578,1085,5.3999996,0.27906975,19.35 - 28.1,-3.3500004,-0.11921709,19.35,28.1,1623196800,1.0,12.632385,0.03992972,2,PNK,1.95925,6.40425,25.685371,-0.9353714,-0.036416505,24.27547,0.47452927,0.019547686,8202843136,3.8646212,15,America/New_York,EDT,-14400000,False,False,0,IPSEN SA,us_market,PRE,0.99,,,28.1,19.35,25.69,24.28,1.58k,1.08k,331.43M,,139.21M,0.00%,0.01%,,,,,,0.3,1.11%,1.00,3.99%,1.05,13.33%,"Jun 08, 2021","May 27, 2021",,,"Dec 30, 2020","Jun 29, 2021",22.55%,29.67%,11.84%,29.47%,2.79B,8.43,8.20%,2.2B,968.1M,626.5M,1.96,37.00%,737.5M,2.23,1.07B,44.99,1.58,6.40,834.9M,502.65M,Value,92650,Healthcare,5700,9,7,"Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",Boulogne-Billancourt,33 1 58 33 50 00,7,1609372800,1625097600,8,France,http://www.ipsen.com,86400,9,"65, quai Georges Gorse",33 1 58 33 50 01,Drug Manufacturersâ€”Specialty & Generic,Cedex
